Loading stock data…
GYRE
$7.80+0.12 (+1.56%)
Market ClosedLast close May 1
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gyre Therapeutics, Inc. in the Healthcare sector is trading at $7.80. The stock is currently 34% below its 52-week high of $11.78, remaining 1.6% above its 200-day moving average. Technical signals show neutral RSI of 52 and bullish MACD crossover, explaining why GYRE maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.80
Potential Downside
95.1%
Whystock Fair Value$0.38
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$18.67+139.3%
Range$18.00 – $20.00
Fundamentals
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$744.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
386.50
Beta
High-beta play. Expect amplified moves vs. the broad market.
6.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.74%
Volume
Today's trading volume
70,795
Recent News
US High Growth Tech Stocks To Watch
The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging opportunities.
Exploring Three High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has seen a significant 15% rise over the past year, with earnings expected to grow by 16% annually. In this context of fluctuating market conditions and promising growth forecasts, identifying high-growth tech stocks involves assessing their potential for innovation and scalability within this dynamic landscape.
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +2.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +15.08% and +57.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader antibody conjugate therapies, in an all-stock transaction valued at approximately $300M. Following the closure of the acquisition, the new combined entity will be a fully integrated biopharmaceutical company with U.S.- and China-based capabilities spanning from discovery to manufacturing